The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...